Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 4Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 18Carcinoma, Hepatocellular 11Stomach Neoplasms 10Esophageal Squamous Cell Carcinoma 10Squamous Cell Carcinoma of Head and Neck 9Lung Neoplasms 8Colorectal Neoplasms 8Rectal Neoplasms 5Advanced Solid Tumor 5Head and Neck Neoplasms 4Triple Negative Breast Neoplasms 3Esophageal Neoplasms 3Cholangiocarcinoma 3Urinary Bladder Neoplasms 2Small Cell Lung Carcinoma 2Neoplasm, Residual 2Nasopharyngeal Carcinoma 2Lymphoma 2Leukemia, Myeloid, Acute 2Colonic Neoplasms 2Biliary Tract Neoplasms 2Advanced Solid Tumour 2Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of External Auditory Canal 1Solid Tumor, Adult 1Solid Tumor 1Small Cell Lung Cancer Extensive Stage 1Simpson-Golabi-Behmel syndrome 1Sarcoma 1Renal Pelvic Carcinoma 1

Interventions

Nivolumab 28pembrolizumab 24cabozantinib 22Ipilimumab 19Specimen Handling 14Magnetic Resonance Spectroscopy 13Axitinib 12lenvatinib 10Radiosurgery 9belzutifan 8CTLA-4 Antigen 7Biopsy 7atezolizumab 6cemiplimab 5Radiotherapy 5Bevacizumab 5toripalimab 4Everolimus 4Blood Specimen Collection 4avelumab 3aldesleukin 3X-Rays 3Sunitinib 3Standard of Care 3Paclitaxel 3zimberelimab 2trastuzumab deruxtecan 2tivozanib 2spartalizumab 2pazopanib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Carcinoma, Renal Cell × tislelizumab × Clear all
NCT06211790 2024-01-18

Proteomic Guided First-line Precision Treatment of Renal Clear Cell Carcinoma

Fudan University

Phase 2 Recruiting
66 enrolled
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡